ReviewNature reviews. Clinical oncology2021
Beneficial autoimmunity improves cancer prognosis.
Review in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center.Current oncology (Toronto, Ont.) · 2024Pooled it
- Antibodies as biomarkers for cancer risk: a systematic review.Clinical and experimental immunology · 2022Pooled it
- Human biomarker navigator.iMeta · 2026Review
- Defining the rules of engagement: B cells, antibodies and cancer control.Cellular & molecular immunology · 2026Review
- Humoral contributions to checkpoint blockade therapy.Journal for immunotherapy of cancer · 2026Article
- DAMP signaling networks: from receptors to diverse pathophysiological functions.Journal of advanced research · 2026Review
- Melanosomes support immune evasion in melanoma.Cellular & molecular immunology · 2026Article
- Oocyte-inspired universal whole-cell vaccines against tumor heterogeneity.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Bright side of the dark genome: antigens for next-gen cancer vaccines.Journal for immunotherapy of cancer · 2026Review
- Essential Thrombocythemia, Acquired von Willebrand Disease, and Acquired Pernicious Anemia: A Case of Potential Beneficial Autoimmunity.ACG case reports journal · 2026Article
- Ruminococcaceae promotes the NLRP3/ASC/Caspase-1 axis-mediated pyroptotic signaling in papillary thyroid carcinoma by upregulating RBM15 to increase the N6-methyladenosine methylation modulation of NLRP3.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Novel perspectives on extracellular vesicles in autoimmune diseases: immunogenicity, inflammation, and immune surveillance.The Journal of clinical investigation · 2026Review
- Vitiligo Signature-Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Dynamic changes in nutritional parameters, inflammatory, and immune biomarkers during (chemo-) radiotherapy for head and neck cancer: a prospective longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer.Nature cancer · 2025Article
- The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage.Pigment cell & melanoma research · 2025Review
- An evolutionary medicine and life history perspective on aging and disease: Trade-offs, hyperfunction, and mismatch.Evolution, medicine, and public health · 2025Review
- Sex bias in tumor immunity: insights from immune cells.Theranostics · 2025Review
- Investigation of sphingolipid-related genes in lung adenocarcinoma.Frontiers in molecular biosciences · 2025Article
- The danger theory of immunity revisited.Nature reviews. Immunology · 2024Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 5 countries.
Funding
Abstract
Many tumour antigens that do not arise from cancer cell-specific mutations are targets of humoral and cellular immunity despite their expression on non-malignant cells. Thus, in addition to the expected ability to detect mutations and stress-associated shifts in the immunoproteome and immunopeptidome (the sum of MHC class I-bound peptides) unique to malignant cells, the immune system also recognizes antigens expressed in non-malignant cells, which can result in autoimmune reactions against non-malignant cells from the tissue of origin. These autoimmune manifestations include, among others, vitiligo, thyroiditis and paraneoplastic syndromes, concurrent with melanoma, thyroid cancer and non-small-cell lung cancer, respectively. Importantly, despite the undesirable effects of these symptoms, such events can have prognostic value and correlate with favourable disease outcomes, suggesting 'beneficial autoimmunity'. Similarly, the occurrence of dermal and endocrine autoimmune adverse events in patients receiving immune-checkpoint inhibitors can have a positive predictive value for therapeutic outcomes. Neoplasias derived from stem cells deemed 'not essential' for survival (such as melanocytes, thyroid cells and most cells in sex-specific organs) have a particularly good prognosis, perhaps because the host can tolerate autoimmune reactions that destroy tumour cells at some cost to non-malignant tissues. In this Perspective, we discuss examples of spontaneous as well as therapy-induced autoimmunity that correlate with favourable disease outcomes and make a strong case in favour of this 'beneficial autoimmunity' being important not only in patients with advanced-stage disease but also in cancer immunosurveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.